Ignite Creation Date:
2025-12-25 @ 2:27 AM
Ignite Modification Date:
2025-12-27 @ 8:06 AM
Study NCT ID:
NCT06242834
Status:
RECRUITING
Last Update Posted:
2025-10-22
First Post:
2024-01-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Sponsor:
Northwestern University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-09-30
Start Date Type:
ACTUAL
Primary Completion Date:
2027-04-24
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-11-24
Completion Date Type:
ESTIMATED
First Submit Date:
2024-01-29
First Submit QC Date:
None
Study First Post Date:
2024-02-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-20
Last Update Post Date:
2025-10-22
Last Update Post Date Type:
ESTIMATED